title: A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization.
abstract: Growth hormone (GH) elicits a variety of biological activities mainly mediated by the GH receptor (GHR), a transmembrane protein that, based on in vitro studies, seemed to function as a homodimer. To test this hypothesis directly, we investigated patients displaying the classic features of Laron syndrome (familial GH resistance characterized by severe dwarfism and metabolic dysfunction), except for the presence of normal binding activity of the plasma GH-binding protein, a molecule that derives from the exoplasmic-coding domain of the GHR gene. In two unrelated families, the same GHR mutation was identified, resulting in the substitution of a highly conserved aspartate residue by histidine at position 152 (D152H) of the exoplasmic domain, within the postulated interface sequence involved in homodimerization. The recombinant mutated receptor protein was correctly expressed at the plasma membrane. It displayed subnormal GH-binding activity, a finding in agreement with the X-ray crystal structure data inferring this aspartate residue outside the GH-binding domain. However, mAb-based studies suggested the critical role of aspartate 152 in the proper folding of the interface area. We show that a recombinant soluble form of the mutant receptor is unable to dimerize, the D152H substitution also preventing the formation of heterodimers of wild-type and mutant molecules. These results provide in vivo evidence that monomeric receptors are inactive and that receptor dimerization is involved in the primary signalling of the GH-associated growth-promoting and metabolic actions.
authors.affiliation: Laboratoire de Génétique Humaine, Institut National de la Santé et de la Recherche Médicale (INSERM) U.91, Hôpital Henri Mondor, Créteil, France.
authors.forename: P
authors.initials: P
authors.lastname: Duquesnoy
authors.forename: M L
authors.initials: ML
authors.lastname: Sobrier
authors.forename: B
authors.initials: B
authors.lastname: Duriez
authors.forename: F
authors.initials: F
authors.lastname: Dastot
authors.forename: C R
authors.initials: CR
authors.lastname: Buchanan
authors.forename: M O
authors.initials: MO
authors.lastname: Savage
authors.forename: M A
authors.initials: MA
authors.lastname: Preece
authors.forename: C T
authors.initials: CT
authors.lastname: Craescu
authors.forename: Y
authors.initials: Y
authors.lastname: Blouquit
authors.forename: M
authors.initials: M
authors.lastname: Goossens
mesh_terms: D000595:Amino Acid Sequence; D000596:Amino Acids / Q000235:genetics; D001483:Base Sequence; D004247:DNA; D004392:Dwarfism / Q000235:genetics* / Q000378:metabolism; D005260:Female; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D010375:Pedigree; D010641:Phenotype; D011487:Protein Conformation; D011986:Receptors, Somatotropin / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D012996:Solutions; D013577:Syndrome
chemical_list: D000596:Amino Acids; D011986:Receptors, Somatotropin; D012996:Solutions; D013006:Growth Hormone; D004247:DNA